Matrix metalloproteinase-9 in spontaneously hypertensive hyperlipidemic rats.

The presence of hypertension and hyperlipidemia accelerates atherosclerosis and increases the risk of ocular disease. Since there were few rat models for atherosclerosis, spontaneously hypertensive rats (SHRs) and spontaneously hyperlipidemic rats (HLRs) were crossbred to obtain a new model: the spontaneously hypertensive hyperlipidemic rat (SHHR). Matrix metalloproteinases (MMPs) play an important role in ocular degeneration. The purpose of this study is to investigate changes in the MMP activities in vitreous and plasma as well as MMP expression in the retinas of SHHRs, which served as a model of vascular degeneration. We used 8-month-old Wistar-Kyoto (WKY) rats and Sprague-Dawley (SD) rats, SHRs, HLRs, and SHHRs. The MMP-2 and MMP-9 activities in plasma and vitreous were examined by zymography. The mRNA expression of MMP-2, MMP-9, and tissue inhibitor of metalloproteinases-3 (TIMP-3) in retina was examined by quantitative PCR. The localized expression of MMP-9 in the retinas was examined by immunostaining. The MMP-9 activity increased significantly in SHHRs compared with all other rats. MMP-9 was observed mainly at the superficial layer of the retina on immunostaining. The MMP-2, MMP-9, and TIMP-3 mRNA in retina was not significantly different in SHHRs as compared with all other rats. Increased MMP-9 activity in vitreous was influenced more intensely from plasma than retina because there was no change in MMP-9 expression in retina, and MMP-9 immunostaining was observed mainly at the surface of the retina, where blood vessels are present. In this study, the complications of hypertension and hyperlipidemia induced increased MMP-9 activity in vitreous and plasma. It is therefore suggested that MMP-9 may be involved in causing this result and in the development of retinal disease.

[1]  G. Gibbons,et al.  The emerging concept of vascular remodeling. , 1994, The New England journal of medicine.

[2]  Yasmin,et al.  Matrix Metalloproteinase-9 (MMP-9), MMP-2, and Serum Elastase Activity Are Associated With Systolic Hypertension and Arterial Stiffness , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[3]  R. Tarnuzzer,et al.  Matrix Metalloproteinase Expression in Human Retinal Microvascular Cells , 1998, Diabetes.

[4]  V. Fuster,et al.  Lewis A. Conner Memorial Lecture. Mechanisms leading to myocardial infarction: insights from studies of vascular biology. , 1994, Circulation.

[5]  R. Caldwell,et al.  TGF-β increases retinal endothelial cell permeability by increasing MMP-9 : Possible role of glial cells in endothelial barrier function , 2001 .

[6]  T. Kumai,et al.  Enhancement of the coagulation system in spontaneously hypertensive and hyperlipidemic rats. , 2005, Journal of atherosclerosis and thrombosis.

[7]  L. Bouter,et al.  Blood pressure, lipids, and obesity are associated with retinopathy: the hoorn study. , 2002, Diabetes care.

[8]  A. Evans,et al.  Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis. , 1999, Circulation.

[9]  Timothy C Greiner,et al.  Matrix metalloproteinases 2 and 9 work in concert to produce aortic aneurysms. , 2002, The Journal of clinical investigation.

[10]  Tien Yin Wong,et al.  Associations between the metabolic syndrome and retinal microvascular signs: the Atherosclerosis Risk In Communities study. , 2004, Investigative ophthalmology & visual science.

[11]  A. Milam,et al.  Tissue inhibitor of metalloproteinases-3 is a component of Bruch's membrane of the eye. , 1997, The American journal of pathology.

[12]  Z. Galis,et al.  Remodeling of Carotid Artery Is Associated With Increased Expression of Matrix Metalloproteinases in Mouse Blood Flow Cessation Model , 2000, Circulation.

[13]  J. Edelman,et al.  Corticosteroids inhibit VEGF-induced vascular leakage in a rabbit model of blood-retinal and blood-aqueous barrier breakdown. , 2004, Experimental eye research.

[14]  Tien Yin Wong,et al.  Hypertensive retinopathy signs as risk indicators of cardiovascular morbidity and mortality. , 2005, British medical bulletin.

[15]  F. Cambien,et al.  Plasma Concentrations and Genetic Variation of Matrix Metalloproteinase 9 and Prognosis of Patients With Cardiovascular Disease , 2003, Circulation.

[16]  D. Heistad,et al.  Arteriosclerosis, Thrombosis, and Vascular Biology, 2004 , 2004 .

[17]  I. Winblad,et al.  Determinants of femoral and carotid artery atherosclerosis , 1994, Journal of internal medicine.

[18]  K. Kashiwagi,et al.  MATRIX METALLOPROTEINASES IN HUMAN DIABETIC AND NONDIABETIC VITREOUS , 2001, Retina.

[19]  M. Takigawa,et al.  Nitric oxide mediates interleukin-1-induced gene expression of matrix metalloproteinases and basic fibroblast growth factor in cultured rabbit articular chondrocytes. , 1998, Journal of biochemistry.

[20]  J. Walsh,et al.  Hypertensive retinopathy. Description, classification, and prognosis. , 1982, Ophthalmology.

[21]  A. Pollock,et al.  Tissue-specific Enhancer-Promoter Interactions Regulate High Level Constitutive Expression of Matrix Metalloproteinase 2 by Glomerular Mesangial Cells (*) , 1995, The Journal of Biological Chemistry.

[22]  D. Gomez,et al.  Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. , 1997, European journal of cell biology.

[23]  Carine Munaut,et al.  Matrix metalloproteinase-9 contributes to choroidal neovascularization. , 2002, The American journal of pathology.

[24]  Y. Hata,et al.  Expression of matrix metalloproteinases and their inhibitors in experimental retinal ischemia-reperfusion injury in rats. , 2002, Experimental eye research.

[25]  D. Tomassoni,et al.  NEUROPROTECTIVE EFFECT OF TREATMENT WITH CALCIUM ANTAGONISTS ON HYPERTENSIVE RETINA , 2002, Clinical and experimental hypertension.

[26]  J. Arenillas,et al.  Matrix Metalloproteinase-9 Pretreatment Level Predicts Intracranial Hemorrhagic Complications After Thrombolysis in Human Stroke , 2003, Circulation.

[27]  B. Haye,et al.  TIMPs as multifacial proteins. , 2004, Critical reviews in oncology/hematology.

[28]  S. Apte,et al.  The Gene Structure of Tissue Inhibitor of Metalloproteinases (TIMP)-3 and Its Inhibitory Activities Define the Distinct TIMP Gene Family (*) , 1995, The Journal of Biological Chemistry.

[29]  N. Matsumoto,et al.  Anti-lipid deposition effect of HMG-CoA reductase inhibitor, pitavastatin, in a rat model of hypertension and hypercholesterolemia. , 2004, Life sciences.

[30]  R. Browne,et al.  Activation of AP-1 and Increased Synthesis of MMP-9 in the Rabbit Retina Induced by Lipid Hydroperoxide , 2006, Current eye research.

[31]  M. Reidy,et al.  Smooth muscle cell migration and matrix metalloproteinase expression after arterial injury in the rat. , 1994, Circulation research.

[32]  N. Occleston,et al.  A prospective study of matrix metalloproteinases in proliferative vitreoretinopathy. , 1998, Investigative ophthalmology & visual science.

[33]  C. Toth,et al.  Matrix metalloproteinases and their inhibitors in human vitreous. , 1998, Investigative ophthalmology & visual science.

[34]  Y. Kitaoka,et al.  Biochemical and morphological characterization of spontaneously hypertensive hyperlipidaemic rats , 2003, Clinical and experimental pharmacology & physiology.

[35]  Shigeyoshi Itohara,et al.  Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis , 2000, Nature Cell Biology.

[36]  Z. Han,et al.  Angiogenesis: state of the art. , 1999, International journal of hematology.

[37]  J. Foidart,et al.  Matrix metalloproteinase family. , 1995, Cell biology international.

[38]  K. Oguchi,et al.  Inhibition of Oxygen-induced Retinal Neovascularization in the Neonatal Rat by Green Tea Extract , 2003 .

[39]  D. Brieger,et al.  Elevated circulating levels of matrix metalloproteinase‐9 and ‐2 in patients with symptomatic coronary artery disease , 2005, Internal medicine journal.

[40]  R. Klein,et al.  Cardiovascular risk factors for retinal vein occlusion and arteriolar emboli: the Atherosclerosis Risk in Communities & Cardiovascular Health studies. , 2005, Ophthalmology.

[41]  T. Kumai,et al.  REDUCED HEPATIC DRUG-METABOLISING ENZYME ACTIVITIES IN SPONTANEOUSLY HYPERLIPIDAEMIC RAT AS AN ANIMAL MODEL OF HYPERCHOLESTEROLAEMIA , 1996 .

[42]  T. Kumai,et al.  Development of hyperfibrinogenemia in spontaneously hypertensive and hyperlipidemic rats: a potentially useful animal model as a complication of hypertension and hyperlipidemia. , 2007, Experimental animals.

[43]  A. Mauviel.  Cytokine regulation of metalloproteinase gene expression , 1993, Journal of cellular biochemistry.

[44]  É. Allaire,et al.  Prevention of aneurysm development and rupture by local overexpression of plasminogen activator inhibitor-1. , 1998, Circulation.

[45]  Bronwyn A. Kingwell,et al.  Matrix Metalloproteinase-9 Genotype Influences Large Artery Stiffness Through Effects on Aortic Gene and Protein Expression , 2004, Arteriosclerosis, thrombosis, and vascular biology.